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We have focused our recent efforts on characterizing the surface properties of 
T-effector cells  in  protection against  syngeneic tumors.  We  have  utilized  a 
mouse model, the C58 mouse/line Ib syngeneic leukemia system, to evaluate and 
characterize the lymphoid subpopulations operative in leukemia immunity (1- 
4). Utilizing an adoptive transfer technique, we have been able to measure the 
protective capacity of lymphocytes derived from the spleen, bone marrow, and 
thymus of both normal and immune donors quantitatively (1). We have shown 
that the protective cell population appears to be Thy 1.2  +, Ig-, and Ly 4.2- T 
cells (4). 
The I  (immune response) region of the mouse major histocompatibility com- 
plex (MHC) codes for a series of lymphocyte membrane alloantigens (Ia), as well 
as for many immunologically related functions, including immune response 
genes, graft versus host reactivity, mixed lymphocyte reactivity, and resistance 
to gross virus  leukemogenesis (5). It is now generally agreed that these Ia 
antigens are expressed on at least a subset ofT cells (6-11).  We thus wished to 
determine any possible role that these Ia expressing T cells may play in tumor 
immunity. 
We report here that the selective removal of the small subpopulation ofT cells 
possessing the Ia determinants coded by the I-A #, I-B #,  and I-J  k regions of the 
MHC of the mouse abrogates the protective capacity of nylon-wool-purified T 
cells against challenge by leukemic cells. 
Materials and Methods 
Mice.  All mice were raised in the breeding colonies at the University of Minnesota or at the 
University of Southern California. C58(H-2  k) mice were maintained in Dr. Lukasewycz's colony at 
the  University of Minnesota.  The  colony was  started  with  breeder  groups  furnished  by  Dr. 
William H.  Murphy at the University of Michigan. The origin of these mice has been described 
(12).  Mice were 8-10 wk old when used experimentally. 
Ib Cells.  The  methods  used  to  prepare  stocks  of Ib  cells were  as  described  previously  (1). 
Spleens were removed from mice moribund with transplanted leukemia and teased into minimum 
essential medium (MEM) supplemented with 5% fetal calf serum (FCS) (Grand Island Biological 
Company, Grand Island, N. Y.). All procedures were carried out aseptically. Total and viable cell 
counts (trypan blue dye exclusion) were performed. 
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Immunization of Mice.  Procedures for immunizing mice to Ib cells have been described (1). In 
brief, fresh Ib cells prepared as described above and at a final concentration of 1 × 107 cells/ml were 
incubated in a 0.02% formalin solution for 18 h at 4°C. Mice received a single i.p. injection (1.0 ml) 
of the formalinized cells and were observed for 15 days to assure that none died of the immunizing 
preparation.  Mice thus immunized could survive a challenge dose of 107 viable Lo cells and served 
as donors of immune spleen cells (12). 
Adoptive Cell Transfer.  Mice were immunosuppressed by cytoxan treatment (250 mg/kg body 
weight); 24 h later they were injected with a counted number of Ib-primed T cells; 24 h  after this 
injection they were  challenged with  a  partially  formalin-killed preparation  of Ib  cells.  These 
preparations  contained  approximately  103  viable  cells  and  are  lethal  to  immunosuppressed, 
unprotected mice (1, 2). 
Spleen Cell Preparation.  Immune spleen cells (ISC) were obtained from mice immunized 15 
days previously. Donor mice were killed by cervical dislocation, and a single cell suspension was 
prepared as described for Ib cells. 
Nylon Wool Columns.  Thymus-derived lymphocytes were prepared from whole ISC prepara- 
tions  using  nylon-wool  (LP-1  Leukopak  Leukocyte  Filter,  Fenwall  Laboratories  Inc.,  Morton 
Grove, Ill.) as described by Julius et al. (13). Such cells were routinely 90-95% Thy-1 positive as 
determined by anti-Thy 1.2 serum and complement treatment.  Less than 5% of these cell popula- 
tions are Ig  ÷ by immunofluorescence. 
Antisera.  Antisera specific for the Ia antigens were produced as previously described (14). Cell 
experiments were performed using a single-peol antiserum (A.TH × B10.HTT)F~ anti-A.TL which 
contains antibodies against the I-A  k, I-B k, and I-J  k regions, but not the I-E and I-C regions. This 
antiserum  might contain anti-Ia.1,  2,  3,  19, plus the specificity coded by Ia-4.  This serum has 
cytotoxic activity for Ia.3 and against promoter T cells (15). 
Antiserum Treatment of Cells.  For blocking experiments  nylon wool-purified T  cells were 
incubated with 2.0 ml of a 1:10 dilution of the anti-Ia serum for 20 min at room temperature and for 
an additional 20 min at 4°C. Appropriate viability counts (trypan blue exclusion) were made at the 
end of each procedure. Cells were then washed by centrifugation in MEM-FCS and resuspended at 
the appropriate concentration. 
To determine if the protective cells carried Ia determinants,  1 ×  107 cells were incubated with 
2.0 ml of a  1:20 dilution of the anti-Ia serum for 20 min at room temperature and 20 min at 4°C, 
centrifuged,  and  resuspended  in  2  ml  of guinea  pig complement  (Microbiological Associates, 
Bethesda, Md.) diluted h2 in MEM, and incubated for 30 min at 37°C. The cells were then washed 
twice by centrifugation in media, counted in a  hemocytometer, and adjusted to the appropriate 
concentration. 
Results and Discussion 
Protective  Capacity  of T  Lymphocytes  Bearing  the  Ia  Determinants.  To 
ascertain the role of Ia  + T lymphocytes in protecting immunosuppressed mice 
against leukemic challenge, we treated nylon wool-purified T-cell populations 
with antisera against a  restricted portion of the I  region of the mouse H-2 
complex. We tested graded log doses ofT cells treated with such antisera or with 
normal mouse serum (NMS),  with and without addition of exogenous comple- 
ment, for their ability to protect against Ib  cell challenge (Table I).  10  6 un- 
treated,  nylon-wool-purified T  cells were able  to protect immunosuppressed 
recipients. This is in agreement with our previous findings showing the protec- 
tive cell bears Thy 1.2 +, Ig-, and Ly 4.2- cell surface antigens (4). Treatment 
with specific antisera alone, NMS alone, complement alone, or with NMS and 
complement does not alter the protective capacity of the transferred T  cells. 
Treatment of the T lymphocytes  with anti-Ia antisera and complement removes 
only 10-15% of the total T-cell population.  The lymphocytes remaining after 
such treatment are not protective, even at the 1 × 10  6  transferred cell level. This 
suggests that the small subpopulation of T cells bearing the Ia determinants 
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TABLE  I 
Elimination of the Protective Class of  Immune T Cells by Treatment with Anti-Ia Serum 
and Complement 
Immune T Cells  Survivors of  leukemic challenge 
No. viable  cells  Experiment no. 
Treated with:  Totals  Percent 
transferred 
I  II  IH 
1  x  10  ~  5/5  5/5  4/4  14/14  100 
1  x  10  ~  3/5  2/5  1/4  6/14  43 
1  x  104  0/5  0/5  0/4  0/14  0 
Anti-la  1  x  10  ~  4/5  5/5  4/4  13/14  93 
Anti-Ia  1 x  1~  ~  2/4  4/5  2/4  8/13  62 
Anti-Ia  1  x  104  0/5  0/5  0/4  0/14  0 
AntiJa +  C  1 x  106  0/5  0/5  0/4  0/14  0 
Anti-Ia  +  C  1 x  10  ~  0/6  0/5  0/4  0/15  0 
Anti-la +  C  1 x  104  0/5  0/5  0/5  0/15  0 
NMS  1 x  10  ~  5/5  5/5  4/4  14/14  100 
NMS  1  x  1~  ~  2/5  3/5  1/5  6/15  40 
NMS  1 x  104  0/5  ND  ND  0/5  0 
NMS +  C  1 x  10'  5/5  5/5  5/5  15/15  100 
NMS +  C  1 x  1~  ~  2/5  3/5  2/4  7/14  50 
NMS +  C  1 ×  i04  0/5  0/5  0/5  0/15  0 
C  1 x  10  ~  4/4  4/5  4/4  12/13  92 
C  1 x 1{~  ~  2/5  ND  1/5  3/10  30 
C  1 x  104  0/5  ND  ND  0/5  0 
No cells  0/5  0/5  0/5  0/15  0 
significant role in  tumor immunity.  We have not completely eliminated the 
possibility that the depletion ofIa  + macrophages may be responsible for the lack 
of protection seen by the treated cell population. This seems unlikely in view of 
our preliminary findings (unpublished) that T-cell populations depleted of mac- 
rophages  by  glass  wool  filtration  are  competent  in  providing  protection. 
Whether this  protective capacity is  relegated to  cells  bearing determinants 
ceded by one, two, or all three of the regions tested is yet to be determined. 
The role of Ia determinants as a  marker for functional T-cell subsets has 
recently been explored.  It  has been shown that the Ia determinants are ex- 
pressed on suppressor T cells and map in the I-J region (16). Further, we have 
recently shown the Ia antigens expressed on concanavalin A-reactive T cells to 
be restricted to the I-J subregion (15). Stout et al. have studied Ia on Fc receptor- 
positive T cells by blocking of Ig binding and have determined that a portion of 
the FcR  ÷ T cells are blocked by antibodies directed at I-A- or I-C-coded determi- 
nants (17). The relationship between the Ia-positive T cells capable of protecting 
mice against leukemic challenge and Ia  ÷ T cells with these other functions is yet 
to be determined. 
It is of interest to point out that normal cells, i.e.,  cells from nonimmune 
donors, possess the capacity to protect against line Ib leukemia, but only with a 
100-fold increase in cells transferred in this assay (1). Studies are now underway 
to determine if this protective capacity of normal cells can also be abrogated by 
specific antisera.  If it cannot,  it would suggest that the Ia determinants are 
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Ia expression on T cells appears more easily detected on activated T cells (18, 19). 
It is important to consider the results reported here with two other pieces of 
information. It has been accepted that Ia antigens are not expressed on cytotoxic 
T cells specific for MHC-coded determinants using negative selection by anti-Ia 
and complement such as presented here (20), although a contradictory result has 
appeared  (21).  The  second bit of information  is that  although  it is clear that 
cytotoxic T  cells specific for MHC determinants  express the phenotype Ly-l-, 
Ly-2+3  + (22), a recent report suggests that the effectors for syngeneic tumor cells 
are Ly-l+2+3  + and therefore represent a distinct subset from the effectors specific 
for MHC alloantigens  (23). The effectors that function in the adoptive transfer 
system  reported  here  for  protection  against  the  syngeneic  Ib  leukemia  are 
clearly  Ia +  in  contrast  to  the  cytotoxic  T  cells  directed  at  the  MHC-coded 
antigens.  This together with the previous report provides strong evidence that 
the effectors in immunity against syngeneic tumors are a different lymphocyte 
class than those directed at allogeneic cells. Assuming we are not eliminating a 
putative  Ia + amplifier  population,  we would predict the  effector cells in this 
system would be Ly-l+2+3+ and Ia  + and represent a uniquely marked T-lympho- 
cyte  subset  distinct  from  both  suppressors  Ly-l-2+3  +,  Ia  +,  and  helpers  Ly- 
1+2-3 -, Ia-. Further studies to determine which Ly antigens are expressed and 
any possible subregion restriction of the Ia antigens expressed on the effectors 
are underway. 
Summary 
We have shown that the selective removal of cells possessing Ia determinants 
coded by the I-A,  I-B,  and I-J  regions  of the H-2  gene  complex completely 
abrogates the protective capacity of nylon-wool-purified T lymphocytes against 
leukemic challenge.  This suggests that the Ia antigen bearing T  cells play an 
important role in tumor immunity. 
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